A retrospective cohort study suggested that people with color blindness may have a higher risk of mortality from bladder ...

ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...

Man patients with MIBC are ineligible for or refuse SOC cisplatin. SunRISe-4 evaluated neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab or cetrelimab monotherapy for pathologic ...

Armistice Capital acquired more shares of ImmunityBio as EMA recommended ANKTIVA approval and Q3 2025 product revenue surged ...

The regulator’s Office of Prescription Drug Promotion (OPDP) has already sent out two letters alleging “false or misleading” ...

GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative ...

GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE(R) natural killer (NK ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extend cas ...

The American Cancer Society’s 2026 Cancer Statistics report shows the five-year survival rate for all cancers has reached a ...

Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis.

A large U.S. health records study suggests that difficulty seeing blood in urine may put color-blind patients at higher risk.